

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077915 A1

(51) International Patent Classification⁷: **A61K 31/436**,
A61P 25/30, 19/02, 9/10

(21) International Application Number: PCT/US03/07334

(22) International Filing Date: 11 March 2003 (11.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/364,188 13 March 2002 (13.03.2002) US

(71) Applicant: **WYETH** [US/US]; a corporation of the State
of Delaware, USA., Five Giralda Farms, Madison, NJ
07940-0874 (US).

(72) Inventor: **ADELMAN, Steven, Jay**; 342 Windy Run
Drive, Doylestown, PA 18901 (US).

(74) Agents: **MILOWSKY, Arnold, S. et al.**; Wyeth, Patent
Law Department, Five Giralda Farms, Madison, NJ 07940-
0874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 03/077915 A1

(54) Title: USE OF RAPAMYCIN FOR INHIBITING OF CELL DEATH

(57) Abstract: This invention provides a method of inhibiting cell death in a mammal in need thereof, which comprises providing

USE OF RAPAMYCIN FOR INHIBITING OF CELL DEATH

BACKGROUND OF THE INVENTION

5 This invention relates a method of inhibiting cell death, more particularly to the use of a rapamycin in the inhibition of cell death, especially following cellular regeneration.

Recent published information supports the concept that that appropriate cell
10 types can repopulate damaged tissue, leading to their repair. Two examples of this are demonstrated by the publications of Orlic (Nature 2001;410:701-705) and Quaini (NEJM 2002;346:5-15). In the publication by Orlic et al., it was found that bone marrow cells can regenerate infarcted myocardium. In the Quaini publication, it was demonstrated that transplanted donor hearts could be populated by recipient cells
15 possessing both stem cell markers and mature myocyte characteristics. Although this information supports the concept of tissue regeneration, in many disease processes, there is an ongoing immune or autoimmune response that will destroy the repopulated cells. Examples of this can be seen in Type I diabetes where the insulin secreting islet cells are initially destroyed by autoimmune processes, and in chronic
20 heart failure where there is a significant loss of functional cardiac myocytes through immune destruction. In these two instances, repopulating stem cells will simply be destroyed again by the immune system.

Rapamycin is a macrocyclic triene antibiotic produced by Streptomyces
25 hygroscopicus, which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749]. Additionally,
rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent
30 4,401,653) has been shown to have antitumor activity.

The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in


preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); R. Y. Calne et al., Lancet 1183 (1978); and U.S. Patent 5,100,899]. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclerosis; in
5 the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies.

Rapamycin is also useful in preventing or treating systemic lupus erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent 5,080,899], insulin dependent diabetes mellitus [U.S. Patent 5,321,009], skin
10 disorders, such as psoriasis [U.S. Patent 5,286,730], bowel disorders [U.S. Patent 5,286,731], smooth muscle cell proliferation and intimal thickening following vascular injury [U.S. Patents 5,288,711 and 5,516,781], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], ocular inflammation [U.S. Patent 5,387,589], malignant carcinomas [U.S. Patent 5,206,018], cardiac inflammatory
15 disease [U.S. Patent 5,496,832], and anemia [U.S. Patent 5,561,138].

DESCRIPTION OF THE INVENTION

This invention provides a method of inhibiting cell death in a mammal in need thereof, which comprises providing an effective amount of a rapamycin to said
20 mammal. In particular, this invention is useful in inhibiting cell death following cellular regeneration in response to a disease, or traumatic injury causing cell death.

As defined herein, the term "a rapamycin" defines a class of immunosuppressive compounds which contain the basic rapamycin nucleus (shown
25 below). The rapamycins of this invention include compounds which may be chemically or biologically modified as derivatives of the rapamycin nucleus, while still retaining immunosuppressive properties. Accordingly, the term "a rapamycin" includes esters, ethers, oximes, hydrazones, and hydroxylamines of rapamycin, as well as rapamycins in which functional groups on the rapamycin nucleus have been
30 modified, for example through reduction or oxidation. The term "a rapamycin" also includes pharmaceutically acceptable salts of rapamycins, which are capable of forming such salts, either by virtue of containing an acidic or basic moiety.



RAPAMYCIN

It is preferred that the esters and ethers of rapamycin are of the hydroxyl groups at the 42- and/or 31-positions of the rapamycin nucleus, esters and ethers of a hydroxyl group at the 27-position (following chemical reduction of the 27-ketone), and that the oximes, hydrazones, and hydroxylamines are of a ketone at the 42- position (following oxidation of the 42-hydroxyl group) and of 27-ketone of the rapamycin nucleus.

Preferred 42- and/or 31-esters and ethers of rapamycin are disclosed in the following patents, which are all hereby incorporated by reference: alkyl esters (U.S. Patent 4,316,885); aminoalkyl esters (U.S. Patent 4,650,803); fluorinated esters (U.S. Patent 5,100,883); amide esters (U.S. Patent 5,118,677); carbamate esters (U.S. Patent 5,118,678); silyl ethers (U.S. Patent 5,120,842); aminoesters (U.S. Patent 5,130,307); acetals (U.S. Patent 5,51,413); aminodiester (U.S. Patent 5,162,333); sulfonate and sulfate esters (U.S. Patent 5,177,203); esters (U.S. Patent 5,221,670); alkoxyesters (U.S. Patent 5,233,036); O-aryl, -alkyl, -alkenyl, and -alkynyl ethers (U.S. Patent 5,258,389); carbonate esters (U.S. Patent 5,260,300); arylcarbonyl and alkoxy carbonyl carbamates (U.S. Patent 5,262,423); carbamates (U.S. Patent 5,302,584); hydroxyesters (U.S. Patent 5,362,718); hindered esters (U.S. Patent 5,385,908); heterocyclic esters (U.S. Patent 5,385,909); gem-disubstituted esters (U.S. Patent 5,385,910); amino alkanolic esters (U.S. Patent

5,389,639); phosphorylcarbamate esters (U.S. Patent 5,391,730); carbamate esters (U.S. Patent 5,411,967); carbamate esters (U.S. Patent 5,434,260); amidino carbamate esters (U.S. Patent 5,463,048); carbamate esters (U.S. Patent 5,480,988); carbamate esters (U.S. Patent 5,480,989); carbamate esters (U.S. Patent 5,489,680); hindered N-oxide esters (U.S. Patent 5,491,231); biotin esters (U.S. Patent 5,504,091); O-alkyl ethers (U.S. Patent 5,665,772); and PEG esters of rapamycin (U.S. Patent 5,780,462). The preparation of these esters and ethers are disclosed in the patents listed above.

10 Preferred 27-esters and ethers of rapamycin are disclosed in U.S. Patent 5,256,790, which is hereby incorporated by reference. The preparation of these esters and ethers are disclosed in the patents listed above.

15 Preferred oximes, hydrazones, and hydroxylamines of rapamycin are disclosed in U.S. Patents 5,373,014, 5,378,836, 5,023,264, and 5,563,145, which are hereby incorporated by reference. The preparation of these oximes, hydrazones, and hydroxylamines are disclosed in the above listed patents. The preparation of 42-oxorapamycin is disclosed in 5,023,263, which is hereby incorporated by reference.

20 Particularly preferred rapamycins include rapamycin [U.S. Patent 3,929,992], rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid [U.S. Patent 5,362,718], and 42-O-(2-hydroxy)ethyl rapamycin [U.S. Patent 5,665,772].

25 When applicable, pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable ~~aids when the rapamycin contains a suitable basic moiety. Salts may also be formed~~
30 from organic and inorganic bases, such as alkali metal salts (for example, sodium, lithium, or potassium) alkaline earth metal salts, ammonium salts, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon

atoms in each alkyl group, and trialkylammonium salts containing 1-6 carbon atoms in each alkyl group, when the rapamycin contains a suitable acidic moiety.

As used in accordance with this invention, the term "providing," with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or substance, or administering a prodrug, derivative, or analog which will form the equivalent amount of the compound or substance within the body.

As used in accordance with this invention, the term "cellular regeneration" means new cell growth to repopulate cells or tissue that have been damaged or killed as a result of a disease or traumatic injury.

In accordance with this inventions, rapamycins are useful in inhibition of cell death, particularly following cellular regeneration after cell death or traumatic injury. In particular, the rapamycins of this invention are useful in inhibiting cell death of regenerating cells in damaged cells or tissue that has resulted from autoimmune diseases, diseases of aging, traumatic injury. Diseases or traumas such as coronary artery disease, congestive heart failure, diabetes (Types I and II), Alzheimer's disease, dementias, memory loss, rheumatoid arthritis, neuropathy, cartilage disorders, and spinal injury or degeneration all cause localized cell death. Such cells include, but are not limited to, pancreatic beta cells, vascular tissue, cardiac tissue, brain cells, including neurons, hepatic cells, liver cells, skin cells, bone cells and spinal tissue. Either upon treatment with various drugs, or by the body's natural regenerative processes the dead or damaged tissue can regenerate. Absent an effective treatment to inhibit cell death, the disease process will kill the regenerating cells. The rapamycins of this invention are useful in inhibiting cell death of the regenerating pancreatic beta cells, vascular tissue, cardiac tissue, brain cells, including neurons, hepatic cells, liver cells, skin cells, bone cells or spinal tissue.

30

It is understood that the effective dosage of the rapamycin may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various

physical factors related to the individual being treated. As used in accordance with invention, satisfactory results may be obtained when the rapamycin is administered in a daily oral dosage of from about 5 μ g to 0.75 mg per kilogram of body weight. The projected daily dosages are expected to vary with route of administration.

5

When a rapamycin is used as part of a combination regimen, dosages of each of the components of the combination are administered during a desired treatment period. The components of the combination may administered at the same time; either as a unitary dosage form containing both components, or as separate dosage units; the components of the combination can also be administered at different times during during a treatment period, or one may be administered as a pretreatment for the other.

Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, intranasally, vaginally, and transdermally. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).

Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or

stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Preferred surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. It is more preferred that poloxamer 188 is used as the surface modifying agent. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). Preferred oral formulations of rapamycins are disclosed in U.S. Patents 5,559,121; 5,536,729; 5,989,591; and 5,985,325, which are hereby incorporated by reference.

In some cases it may be desirable to administer the compounds directly to the airways in the form of an aerosol.

The compounds of this invention may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparation contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol),

suitable mixtures thereof, and vegetable oils. Preferred parenteral formulations for administering a rapamycin are disclosed in U.S. Patents 5,530,006; 5,516,770; and 5,616,588, which are hereby incorporated by reference.

- 5 Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used.

CLAIMS

What is claimed is:

- 5 1. A method of inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.
- 10 2. The method according to claim 1, wherein the cellular regeneration occurs following cell or tissue damage caused by coronary artery disease, congestive heart failure, diabetes (Types I and II), Alzheimer's disease, dementias, memory loss, rheumatoid arthritis, neuropathy, cartilage disorders, or spinal injury or degeneration.
- 15 3. The method according to claim 1 or claim 2, wherein the rapamycin is rapamycin.
4. The method according to claim 1 or claim 2, wherein the rapamycin is a ester, ether, oxime, hydrazone, or hydroxylamine of rapamycin
- 20 5. The method according to claim 4, wherein the rapamycin is a 42-ester or 42-ether of rapamycin.
6. The method according to claim 5, wherein the rapamycin is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.
- 25 7. The method according to claim 5, wherein the rapamycin is 42-O-(2-hydroxy)ethyl rapamycin.
- 30 8. A method of inhibiting cell death of pancreatic beta cells, vascular tissue, cardiac tissue, brain cells, including neurons, hepatic cells, liver cells, skin cells, bone cells or spinal tissue following cellular regeneration of such cells or tissue in a mammal in need thereof, which comprises providing said mammal an effective amount of a rapamycin.

9. The method according to claim 8, wherein the rapamycin is rapamycin.
10. The method according to claim 8, wherein the rapamycin is a ester,
5 ether, oxime, hydrazone, or hydroxylamine of rapamycin.
11. The method according to claim 10, wherein the rapamycin is a 42-ester
or 42-ether of rapamycin.
- 10 12. The method according to claim 11, wherein the rapamycin is rapamycin
42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.
13. The method according to claim 11, wherein the rapamycin is 42-O-(2-
hydroxy)ethyl rapamycin.
15
14. A method of enhancing cell regeneration in a mammal in need thereof,
which comprises providing said mammal an effective amount of a rapamycin.
15. The method according to claim 14, wherein the rapamycin is
20 rapamycin.
16. The method according to claim 14, wherein the rapamycin is a ester,
ether, oxime, hydrazone, or hydroxylamine of rapamycin.
- 25 17. The method according to claim 16, wherein the rapamycin is a 42-ester
or 42-ether of rapamycin.
18. The method according to claim 17, wherein the rapamycin is rapamycin
42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.
30
19. The method according to claim 17, wherein the rapamycin is 42-O-(2-
hydroxy)ethyl rapamycin.

20. Use of a rapamycin for the preparation of a medicament for inhibiting cell death following cellular regeneration in a mammal.

21. Use of a rapamycin for the preparation of a medicament for inhibiting cell death of pancreatic beta cells, vascular tissue, cardiac tissue, brain cells, including neurons, hepatic cells, liver cells, skin cells, bone cells or spinal tissue following cellular regeneration of such cells or tissue in a mammal.

22. Use of a rapamycin for the preparation of a medicament for enhancing cell regeneration in a mammal.

23. Use according to any one of claims 20 to 22, wherein the rapamycin is rapamycin.

24. Use according to any one of claims 20 to 22, wherein the rapamycin is a ester, ether, oxime, hydrazone, or hydroxylamine of rapamycin.

25. Use according to claim 24, wherein the rapamycin is a 42-ester or 42-ether of rapamycin.

26. Use according to claim 25, wherein the rapamycin is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.

27. Use according to claim 25, wherein the rapamycin is 42-O-(2-hydroxy)ethyl rapamycin.

INTERNATIONAL SEARCH REPORT

 Internat| Application No
 PCT/US 03/07334

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/436 A61P25/30 A61P19/02 A61P9/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 778 023 A (AMERICAN HOME PROD) 11 June 1997 (1997-06-11) page 1, line 51 page 1, line 56,57; claims 1-6,9 ---	1-5, 8-11, 20-25
P,X	WO 03 018573 A (WYETH) 6 March 2003 (2003-03-06) claims 1-6,9,11,20,21,24,27 page 8, line 15-20 page 9, line 4 ---	1-27
P,X	WO 03 018574 A (WYETH) 6 March 2003 (2003-03-06) claims 1,3-9,11,14,17,21,23,24 --- -/--	1-27
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
24 July 2003		01/08/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Veronese, A

INTERNATIONAL SEARCH REPORT

Internal ☐ Application No

PCT/us 03/07334

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 40140 A (GUILFORD PHARM INC ;UNIV JOHNS HOPKINS MED (US)) 19 December 1996 (1996-12-19) page 7, line 18 -page 8, line 2 claims 1,2,6,11,13,16 ----	14-16
X	WO 01 97809 A (AMERICAN HOME PROD) 27 December 2001 (2001-12-27) claims 1,2,8,23,24 ----	1-27
X	WO 99 15530 A (ABBOTT LAB) 1 April 1999 (1999-04-01) examples 1A,1B,2,2A, page 10, line 21,22 page 12, line 16,22 ----	1-27
P, X	WO 02 26746 A (AMERICAN HOME PROD) 4 April 2002 (2002-04-04) page 10, line 9-13,23; claims 1,15-18,21 -----	1,2,8, 14,21,22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/07334

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/us 03/07334

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0778023	A	11-06-1997	AT 234095 T	15-03-2003
			AU 700653 B2	14-01-1999
			AU 7417896 A	12-06-1997
			BR 9605895 A	18-08-1998
			CA 2192298 A1	08-06-1997
			CN 1159915 A ,B	24-09-1997
			CZ 9800064 A3	17-06-1998
			CZ 9603544 A3	18-03-1998
			DE 69626610 D1	17-04-2003
			DK 778023 T3	30-06-2003
			EP 0778023 A1	11-06-1997
			HU 9603370 A2	28-05-1997
			IL 119778 A	14-07-1999
			JP 9183727 A	15-07-1997
			NO 965238 A	09-06-1997
			NZ 299888 A	23-02-2001
			SK 154796 A3	10-09-1997
			TW 427904 B	01-04-2001
			ZA 9610245 A	05-06-1998
WO 03018573	A	06-03-2003	WO 03018573 A1	06-03-2003
			US 2003114477 A1	19-06-2003
WO 03018574	A	06-03-2003	WO 03018574 A1	06-03-2003
			US 2003100577 A1	29-05-2003
WO 9640140	A	19-12-1996	US 5798355 A	25-08-1998
			US 5696135 A	09-12-1997
			AU 4879399 A	25-11-1999
			AU 710423 B2	23-09-1999
			AU 6162296 A	30-12-1996
			BG 102072 A	31-08-1998
			BR 9608485 A	06-07-1999
			CA 2206824 A1	19-12-1996
			CH 689541 A5	15-06-1999
			CZ 9702329 A3	15-07-1998
			DE 19680255 T0	05-06-1997
			DK 125696 A	20-12-1996
			EA 1379 B1	26-02-2001
			EE 9700331 A	15-06-1998
			EP 0777478 A1	11-06-1997
			ES 2138518 A1	01-01-2000
			ES 2166740 A1	16-04-2002
			FI 964137 A	15-01-1997
			GB 2305605 A ,B	16-04-1997
			HK 1013254 A1	16-06-2000
			HU 9900816 A2--	28-07-1999
			JP 3060373 B2	10-07-2000
			JP 8333256 A	17-12-1996
			LT 98002 A ,B	25-02-1999
			LU 88834 A1	15-01-1997
			LV 11986 A	20-03-1998
			LV 11986 B	20-09-1998
			NO 974290 A	04-12-1997
			NZ 310767 A	24-11-2000
			PL 323381 A1	30-03-1998
			SE 9604097 A	08-12-1996
			SI 9620089 A	30-04-1999

INTERNATIONAL SEARCH REPORT

 Internat Application No
 PCT/US 03/07334

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9640140	A		SK 161097 A3	04-11-1998
			WO 9640140 A1	19-12-1996
			US 6022878 A	08-02-2000
			US 2003114365 A1	19-06-2003
			US 2002052372 A1	02-05-2002
			US 5843960 A	01-12-1998
			US 5846981 A	08-12-1998
			ZA 9608981 A	25-05-1998

WO 0197809	A	27-12-2001	AU 6844601 A	02-01-2002
			BR 0111601 A	01-07-2003
			CA 2412636 A1	27-12-2001
			CZ 20024115 A3	18-06-2003
			EP 1292302 A2	19-03-2003
			NO 20026008 A	13-12-2002
			WO 0197809 A2	27-12-2001
			US 2002013335 A1	31-01-2002

WO 9915530	A	01-04-1999	AU 745576 B2	21-03-2002
			AU 9581998 A	12-04-1999
			BG 104316 A	29-12-2000
			BR 9812305 A	05-09-2000
			CA 2303934 A1	01-04-1999
			CN 1271361 T	25-10-2000
			EP 1015459 A1	05-07-2000
			HU 0004556 A2	28-10-2001
			JP 2001517671 T	09-10-2001
			NO 20001438 A	26-05-2000
			PL 339455 A1	18-12-2000
			SK 4172000 A3	14-08-2000
			TR 200000778 T2	21-07-2000
			WO 9915530 A1	01-04-1999
			ZA 9808750 A	01-04-1999

WO 0226746	A	04-04-2002	AU 9273901 A	08-04-2002
			WO 0226746 A2	04-04-2002
			US 2002061903 A1	23-05-2002